Tue.May 21, 2024

article thumbnail

AstraZeneca sets sights on $80B in revenue by 2030

Bio Pharma Dive

The U.K. pharma expects to launch 20 new drugs by then, among them complex medicines for cancer as well as treatments for weight loss.

Medicine 310
article thumbnail

Roche’s PI3K inhibitor secures breakthrough status in breast cancer

Pharmaceutical Technology

Roche announced an FDA breakthrough therapy designation for its inavolisib/Ibrance combination therapy.

246
246
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AltruBio lands up to $225M after shift to immune drug research

Bio Pharma Dive

Since pivoting from oncology, the startup has raised close to $300 million and advanced an ulcerative colitis drug into mid-stage testing.

Drugs 290
article thumbnail

Eerie Personality Changes Sometimes Happen After Organ Transplants

AuroBlog - Aurous Healthcare Clinical Trials blog

The idea that the heart contains the very ‘essence’ of a person might be more than just a spiritual concept. Ever since the first human heart transplants back in 1967, patients have reported, often reluctantly, some eerie and inexplicable changes to their personalities.

article thumbnail

Bridging Innovation & Patient Care: The Growing Role of AI

Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.

AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!

article thumbnail

AstraZeneca’s $80B sales plan leans on cancer drug expansion

Bio Pharma Dive

The U.K. drugmaker aims to catch up in developing new tumor-fighting technologies — areas where it has lagged behind leaders like Novartis and J&J.

Sales 268
article thumbnail

NHS addresses shortage of ethnic organ and blood donors with £600,000 funding

Pharma Times

The funding aims to reduce health inequalities in these groups and save more lives

146
146

More Trending

article thumbnail

NIHR awards HealthTech Research Centre Network £5m to advance health innovations

Pharma Times

The network will support the development, evaluation and adoption of innovative health and care technology

Research 144
article thumbnail

Lilly partners with Aktis, deepening radiopharma investment

Bio Pharma Dive

The collaboration, which gives Lilly access to Aktis’ technology in return for $60 million, adds to a flurry of dealmaking in the radiopharma field.

173
173
article thumbnail

Big Pharma Layoffs by the Thousands: Are Bayer and BMS Harbingers of More?

BioSpace

Patent cliffs and other factors may lead other large drugmakers to embrace similar cost-cutting measures, experts tell BioSpace.

143
143
article thumbnail

Lilly collaborates with Aktis to strengthen radiopharma portfolio

Pharmaceutical Technology

Aktis will receive $60m in an upfront payment from Lilly, with the biotech eligible for up to $1.1bn in milestone payments and royalties.

130
130
article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

AstraZeneca sets lofty target of $80bn in revenues by 2030

pharmaphorum

AstraZeneca CEO Pascal Soriot says group revenues can reach $80bn by 2030, fuelled by a pipeline that features 'many' potential $5bn-plus candidates.

119
119
article thumbnail

Pheon cashes in on ADC trend and raises $120m in Series B

Pharmaceutical Technology

The UK-based company plans to use the proceeds for financing the proof-of-concept clinical trials for its ADC pipeline.

article thumbnail

FDA competition seeks digital endpoints for Parkinson’s

pharmaphorum

FDA is asking artificial intelligence teams to develop a digital endpoint tool to study freezing of gait, a symptom of Parkinson’s that can have a serious impact on patients.

article thumbnail

Larimar resumes nomlabofusp programme after FDA lifts partial hold

Pharmaceutical Technology

Larimar will continue the open label extension study in Friedreich’s ataxia with results expected in Q4 this year.

130
130
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

The commercialisation of quantum science in pharma

pharmaphorum

In today’s podcast, web editor Nicole Raleigh speaks with PASQAL’S technical business developer Europe, Krisztian Benyo, PhD, about the pharma applications and commercialisation of quantum science.

article thumbnail

Glenmark to market BeiGene’s oncology medicines in India

Pharmaceutical Technology

Glenmark has entered into an exclusive agreement with BeiGene to market and distribute two Beigene oncology medicines in India.

Medicine 130
article thumbnail

Closing the bipolar diagnosis gap for Black Americans

pharmaphorum

Despite the rate of bipolar disorder being the same among Black Americans as other Americans, there exists a significant disparity in diagnosis and subsequent treatment. Many Black Americans with bipolar disorder remain undiagnosed and untreated.

110
110
article thumbnail

AmplifyBio and Xcell enter TCR T-cell therapy manufacturing deal

Pharmaceutical Technology

AmplifyBio and Xcell Biosciences have announced a strategic collaboration to manufacture engineered T-cell receptor (TCR) therapies.

article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

EU rules PTC’s Duchenne drug can stay on the market

pharmaphorum

Going against the advice of the CHMP, the EU has said that PTC Therapeutics’ Translarna therapy for Duchenne muscular dystrophy should stay on the market

Marketing 105
article thumbnail

AstraZeneca to establish $1.5bn ADC production site in Singapore

Pharmaceutical Technology

AstraZeneca is set to invest $1.5bn in a new manufacturing facility in Singapore dedicated to the production of antibody drug conjugates.

article thumbnail

New patent for Merck Sharp drug BELSOMRA

Drug Patent Watch

Annual Drug Patent Expirations for BELSOMRA Belsomra is a drug marketed by Merck Sharp Dohme and is included in one NDA. It is available from one supplier.

Drugs 105
article thumbnail

FDA grants approval for two Eylea biosimilars for eye conditions

Pharmaceutical Technology

The US FDA has approved Yesafili and Opuviz, two interchangeable biosimilars to Eylea, for macular degeneration and other eye conditions.

130
130
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

AstraZeneca, on fast track of growth, sets revenue target at $80B by 2030

Fierce Pharma

A decade ago, with AstraZeneca in decline and some investors urging the drugmaker to sell out to Pfizer, new CEO Pascal Soriot presented an audacious plan to hike revenue to $45 billion by 2023. | After AstraZeneca achieved Pascal Soriot's ambitious $45-billion-by-2023 revenue goal, the CEO is thinking big again. On Tuesday morning, AZ unveiled its new plan to swell its revenue to $80 billion by 2030.

103
103
article thumbnail

Praxis on nurturing the patient journey making people feel seen and heard

Outsourcing Pharma

Clinical Trials Day is organized and promoted by the Association of Clinical Research Professionals (ACRP) for the last ten years.

article thumbnail

Biogen Beefs Up Immuno Pipeline with Potential $1.8B HI-Bio Acquisition

BioSpace

Days after backing out of two Ionis-partnered neuro programs, Biogen has inked a potential $1.8 billion buy of Human Immunology Biosciences and boosting its late-stage immunology pipeline.

103
103
article thumbnail

Internal budgets ‘holding back pharma’s digital evolution’

pharmaphorum

Digital investment in the pharma sector is continuing at a steady pace but could fall behind what is needed to deliver true transformation of their businesses.

102
102
article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

9 Top Biopharma CEO-to-Employee Pay Gaps

BioSpace

Despite weathering a difficult year, biopharma continues to see massive pay gaps between CEOs and their median employees, with top executives often earning hundreds of times more.

102
102
article thumbnail

Plants and vaccine adjuvants: BSI’s sustainable trees in a lab

pharmaphorum

Discover how the Quillaja saponaria tree is revolutionising vaccine development as a sustainable, natural adjuvant. Learn about BSI's innovative work harnessing the power of this remarkable plant.

Vaccine 100
article thumbnail

Patient-Centered Research in Real-World Settings: Essentials of Embedded Pragmatic Clinical Trials Workshop: SCT (May 2024)

Rethinking Clinical Trials

May 19, 2024: The NIH Pragmatic Trials Collaboratory hosted a Pre-Conference Workshop at the 2022 Health Care Systems Research Network (HCSRN) Annual Conference. This training workshop introduces concepts in the design, conduct, and implementation of embedded pragmatic clinical trials (ePCTs), and provides firsthand ePCT experiences and case studies from the NIH Pragmatic Trials Collaboratory Trials.

article thumbnail

Pharma Pulse 5/21/24: Hims & Hers Announces Access to GLP-1 Injections, The Impact of the Presidential Election on Pharma & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

99
article thumbnail

Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud